BIODESIX INC (57)

Browse by Contract Category

Contracts

Amendment No. 2 to Asset Purchase Agreement and Plan of Reorganization (Filed With SEC on August 10, 2021)
First Amendment to the Non-Exclusive License Agreement between Bio-Rad Laboratories, Inc., and Biodesix, Inc., dated May 24, 2021 (Filed With SEC on August 10, 2021)
Forms of Restricted Stock Unit Award Grant Notice and Award Agreement under the 2020 Equity Incentive Plan (Filed With SEC on August 10, 2021)
Loan and Security Agreement, dated March 19, 2021 (Filed With SEC on March 23, 2021)
Description of Securities Registered Under Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 16, 2021)
Form of Indemnification Agreement, by and between Biodesix, Inc. and each of its directors and executive officers (Filed With SEC on October 14, 2020)
Office Lease between Aero-Tech Investments, LLC and Biodesix, Inc., dated October 5, 2011 (Filed With SEC on October 9, 2020)
Forms of Stock Option Grant Notice, Option Agreement and Notice of Exercise under the 2020 Equity Incentive Plan (Filed With SEC on March 16, 2021)
Biodesix, Inc. 2020 Employee Stock Purchase Plan (Filed With SEC on October 26, 2020)
Biodesix, Inc. 2020 Equity Incentive Plan (Filed With SEC on October 26, 2020)
Specimen stock certificate evidencing shares of Common Stock (Filed With SEC on October 21, 2020)
Form of Underwriting Agreement (Filed With SEC on October 21, 2020)
Letter from Bio-Rad Laboratories, Inc. dated August 14, 2020 (Filed With SEC on October 21, 2020)
Letter from Bio-Rad Laboratories, Inc. dated August 7, 2020 (Filed With SEC on October 21, 2020)
Form of Stock Option Grant Notice under the 2016 Equity Incentive Plan (Filed With SEC on October 9, 2020)
Form of Option Agreement under the 2016 Equity Incentive Plan (Filed With SEC on October 9, 2020)
Form of Notice of Exercise under the 2016 Equity Incentive Plan (Filed With SEC on October 9, 2020)
Form of Stock Option Grant Notice under the Biodesix, Inc. Bonus-To-Options Program (Filed With SEC on October 9, 2020)
Form of Option Agreement under the Biodesix, Inc. Bonus-To-Options Program (Filed With SEC on October 9, 2020)
Co-Development and Collaboration Agreement between AVEO Pharmaceuticals, Inc., and Biodesix, Inc., dated April 9, 2014, as amended October 14, 2016 (Filed With SEC on October 9, 2020)
Loan and Security Agreement, by and among Innovatus Life Sciences Lending Fund I, LP, the Lenders listed therein, and Biodesix, Inc., dated February 23, 2018 (Filed With SEC on October 9, 2020)
IP Assignment Agreement between Oncimmune Limited, and Biodesix, Inc., dated October 31, 2019 (Filed With SEC on October 9, 2020)
IP License Agreement between Oncimmune Limited, and Biodesix, Inc., dated October 31, 2019 (Filed With SEC on October 9, 2020)
Non-Exclusive License Agreement between Bio-Rad Laboratories, Inc., and Biodesix, Inc., dated August 1, 2019 (Filed With SEC on October 9, 2020)
Supply Agreement between Biodesix, Inc., and Oncimmune, dated October 31, 2019 (Filed With SEC on October 9, 2020)
Supply Agreement between Bio-Rad Laboratories, Inc., and Biodesix, Inc., dated August 1, 2019 (Filed With SEC on October 9, 2020)
Form of Option Agreement under the Amended and Restated 2006 Employee, Director and Consultant Stock Plan (Filed With SEC on October 9, 2020)
Form of Notice of Exercise under the Amended and Restated 2006 Employee, Director and Consultant Stock Plan (Filed With SEC on October 9, 2020)
Form of Stock Option Grant Notice under the Amended and Restated 2006 Employee, Director and Consultant Stock Plan (Filed With SEC on October 9, 2020)
Biodesix, Inc. Amended and Restated 2006 Employee, Director and Consultant Stock Plan, as amended to date (Filed With SEC on October 9, 2020)
Warrant held by Innovatus Life Sciences Lending Fund I, LP, to Purchase Series G Preferred Stock, dated February 23, 3018 (Filed With SEC on October 2, 2020)
Secured Promissory Note held by Innovatus Life Sciences Lending Fund I, LP, in Biodesix, Inc., dated February 23, 2018 (Filed With SEC on October 2, 2020)
Biodesix, Inc. 2016 Equity Incentive Plan, as amended to date (Filed With SEC on October 2, 2020)
Biodesix, Inc., First Amended Bonus-to-Options Program, adopted by the Board of Directors on October 15, 2010 (Filed With SEC on October 2, 2020)
Biodesix, Inc., Second Amended Bonus-to-Options Program, adopted by the Board of Directors on June 21, 2011 (Filed With SEC on October 2, 2020)
Biodesix, Inc., Third Amended Bonus-to-Options Program, adopted by the Board of Directors on December 31, 2015 (Filed With SEC on October 2, 2020)
Executive Employment Letter, by and between Biodesix, Inc. and Scott Hutton, dated February 16, 2018 (Filed With SEC on October 2, 2020)
Executive Employment Letter, by and between Biodesix, Inc. and Scott Hutton, dated February 23, 2020 (Filed With SEC on October 2, 2020)
Employment Letter, by and between Biodesix, Inc. and Robin Harper Cowie, dated March 11, 2011 (Filed With SEC on October 2, 2020)
Executive Employment Letter, by and between Biodesix, Inc. and Robin Harper Cowie, dated February 23, 2020 (Filed With SEC on October 2, 2020)
Consulting Agreement, by and between David Brunel and Biodesix, Inc., dated September 19, 2020 (Filed With SEC on October 2, 2020)
Lease Assignment of De Soto Facility, dated November 1, 2019 (Filed With SEC on October 2, 2020)
Limited Consent Agreement and Second Amendment to Loan and Security Agreement, by and among Innovatus Life Sciences Lending Fund I, LP, the Lenders listed therein, and Biodesix,... (Filed With SEC on October 2, 2020)
Patent Assignment between Biodesix, Inc., and Integrated Diagnostics, Inc., dated June 30, 2018 (Filed With SEC on October 2, 2020)
Contingent Value Rights Agreement between Biodesix, Inc. and Holders on Schedule A mentioned within, dated February 22, 2016 (Filed With SEC on October 2, 2020)
Asset Purchase Agreement among Biodesix, Inc., Integrated Diagnostics, Inc., and the stockholders of Integrated Diagnostics, Inc., listed therein, dated June 30, 2018 (Filed With SEC on October 2, 2020)
Asset Purchase Agreement between Oncimmune Limited and Biodesix, Inc., dated June 27, 2019, as amended to date (Filed With SEC on October 2, 2020)
COVID-19 Testing Laboratory Services Agreement by and between Biodesix, Inc., and Centura Health Corporation, dated April 3, 2020 (Filed With SEC on October 2, 2020)
First Amendment to COVID-19 Testing Laboratory Services Agreement by and between Biodesix, Inc. and Centura Health Corporation, dated April 23, 2020 (Filed With SEC on October 2, 2020)
Second Amendment to COVID-19 Testing Laboratory Services Agreement by and between Biodesix, Inc. and Centura Health Corporation, dated May 27, 2020 (Filed With SEC on October 2, 2020)
Third Amendment to COVID-19 Testing Laboratory Services Agreement by and between Biodesix, Inc. and Centura Health Corporation, dated August 7, 2020 (Filed With SEC on October 2, 2020)
Contract Agreement between Biodesix, Inc. and the Colorado Department of Public Health and Environment, dated September 11, 2020 (Filed With SEC on October 2, 2020)
Material Transfer Agreement by and between Biodesix, Inc. and Bio-Rad Laboratories, Inc., dated March 23, 2020 (Filed With SEC on October 2, 2020)
First Amendment to Material Transfer Agreement by and between Biodesix, Inc. and Bio-Rad Laboratories, Inc. dated April 3, 2020 (Filed With SEC on October 2, 2020)
Material Transfer Agreement by and between Biodesix, Inc. and Bio-Rad Laboratories, Inc., dated April 17, 2020 (Filed With SEC on October 2, 2020)
Price Agreement by and between Biodesix, Inc. and Bio-Rad Laboratories, Inc., dated May 12, 2020 (Filed With SEC on October 2, 2020)
Eleventh Amended and Restated Investor Rights Agreement, by and among Biodesix, Inc. and the investors listed on Exhibit A thereto, dated October 10, 2018 (Filed With SEC on October 2, 2020)